Pricing Log in Create free account
Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue
+36.3%
EPS
+36.0%
Free cash flow
+3.85%
Total debt
−26.6%

Quarter to September 2026, against a year earlier

905.02 2.12 +0.23%
Market cap
$93.4B
P/E
19.2×
Fwd P/E
19.2×
Dividend yield
0.41%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. 10-Q filed Aug 1, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 6:56 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 29, 2025: 11 added · 4 removed · 30 modified; 4 with only figures updated

  1. Modified · Products

    Product (continued) | Disease | Territory U.S. | EU | Japan Dupixent® (dupilumab) Injection(b) | Atopic dermatitis (in adults, adolescents, and pediatrics aged 6 months and older) | a | a | a Asthma (in adults and adolescents) | a | a | a Asthma (in pediatrics 6–11 years of age) | a | a Chronic rhinosinusitis with nasal polyposis ("CRSwNP") (in adults) | a | a | a CRSwNP (in adolescents) | a Chronic obstructive pulmonary disease ("COPD") | a | a | a Eosinophilic esophagitis ("EoE") (in adults, adolescents, and pediatrics aged 1 year and older) | a | a Prurigo nodularis | a | a | a Chronic spontaneous urticaria ("CSU") (in adults and adolescents) | a | a Bullous pemphigoid | a Libtayo® (cemiplimab) Injection | Metastatic or locally advanced first-line non-small cell lung cancer ("NSCLC") | a | a Metastatic or locally advanced first-line NSCLC (in combination with chemotherapy) | a | a Metastatic or locally advanced basal cell carcinoma ("BCC") | a | a Metastatic or locally advanced cutaneous squamous cell carcinoma ("CSCC") | a | a Metastatic or recurrent second-line cervical cancer | a | a Praluent® (alirocumab) Injection(c) | LDL-lowering in heterozygous familial hypercholesterolemia ("HeFH") or clinical atherosclerotic cardiovascular disease ("ASCVD") | a | a HeFH in pediatrics and adolescents (8–17 years of age) | a | a Cardiovascular risk reduction in patients with established cardiovascular disease | a | a Homozygous familial hypercholesterolemia ("HoFH") | a Kevzara® (sarilumab) Injection(b) | Rheumatoid arthritis ("RA") | a | a | a Polymyalgia rheumatica ("PMR") | a | a Polyarticular juvenile idiopathic arthritis ("pJIA") | a | a REGEN-COV®(d) | COVID-19 | a | a Evkeeza® (evinacumab) Injection(ed) | HoFH (in adults, adolescents, and pediatrics) | a | a | a OrdsponoTM (odronextamab) | Follicular lymphoma ("FL") | a Diffuse large B-cell lymphoma ("DLBCL") | a LynozyficTM (linvoseltamab) | Relapsed/refractory multiple myeloma | a | a Inmazeb® (atoltivimab, maftivimab, and odesivimab) Injection | Infection caused by Zaire ebolavirus | a Veopoz® (pozelimab) Injection | CD55-deficient protein-losing enteropathy ("CHAPLE") (in adults, adolescents, and pediatrics aged 1 year and older) | a